JP4842817B2 - 神経保護二環式化合物およびその使用方法 - Google Patents

神経保護二環式化合物およびその使用方法 Download PDF

Info

Publication number
JP4842817B2
JP4842817B2 JP2006525396A JP2006525396A JP4842817B2 JP 4842817 B2 JP4842817 B2 JP 4842817B2 JP 2006525396 A JP2006525396 A JP 2006525396A JP 2006525396 A JP2006525396 A JP 2006525396A JP 4842817 B2 JP4842817 B2 JP 4842817B2
Authority
JP
Japan
Prior art keywords
substituted
compound
methyl
allyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006525396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504235A (ja
JP2007504235A5 (https=
Inventor
マーガレット アン ブリンブル
ジァン グァン
フランク シーグ
Original Assignee
ニューレン ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューレン ファーマシューティカルズ リミテッド filed Critical ニューレン ファーマシューティカルズ リミテッド
Publication of JP2007504235A publication Critical patent/JP2007504235A/ja
Publication of JP2007504235A5 publication Critical patent/JP2007504235A5/ja
Application granted granted Critical
Publication of JP4842817B2 publication Critical patent/JP4842817B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2006525396A 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法 Expired - Lifetime JP4842817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49995603P 2003-09-03 2003-09-03
US60/499,956 2003-09-03
PCT/US2004/028308 WO2005023815A2 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and methods for their use

Publications (3)

Publication Number Publication Date
JP2007504235A JP2007504235A (ja) 2007-03-01
JP2007504235A5 JP2007504235A5 (https=) 2007-10-04
JP4842817B2 true JP4842817B2 (ja) 2011-12-21

Family

ID=34272894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525396A Expired - Lifetime JP4842817B2 (ja) 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法

Country Status (9)

Country Link
US (2) US8067425B2 (https=)
EP (1) EP1664050B1 (https=)
JP (1) JP4842817B2 (https=)
DK (1) DK1664050T3 (https=)
ES (1) ES2564803T3 (https=)
HU (1) HUE028528T2 (https=)
PL (1) PL1664050T3 (https=)
SI (1) SI1664050T1 (https=)
WO (1) WO2005023815A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
EP1648873A4 (en) * 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd NEUROPROTECTIVE MACROCYLIC COMPOUNDS AND METHODS OF THEIR APPLICATION
EP1622633B1 (en) 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
WO2008063311A2 (en) * 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8519127B2 (en) * 2003-09-03 2013-08-27 Mike John Bickerdike Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
JP6465803B2 (ja) * 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EP3024463B1 (en) 2013-07-25 2020-03-25 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
KR20240155382A (ko) 2016-05-26 2024-10-28 가부시키가이샤 아미노 압 수면 개선제
EP3512520B1 (en) 2016-09-15 2023-06-21 City of Hope Dithio derivatives of epidithiodiketopiperazine (etp)
EP4663182A2 (en) 2018-03-16 2025-12-17 Scent Science International Inc. Prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent
CN112423774A (zh) * 2018-05-15 2021-02-26 L·H·L·特兰 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法
CA3158406A1 (en) 2019-10-22 2021-04-29 Neuren Pharmaceuticals Limited Bicyclic compounds and methods for their use in treating pitt hopkins syndrome
GEAP202316350A (en) * 2021-02-12 2023-10-25 Neuren Pharmaceuticals Ltd Treatments of prader-willi syndrome
JP2024545685A (ja) * 2021-12-17 2024-12-10 ザ シージーピー ラボ リミテッド Ｃｇｐの動物、真菌及び海洋供給源、並びに疾患管理のための、並びに非神経学的及び／又は神経学的状態の治療のための増大したｃｇｐ濃度
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525850A (ja) * 1998-02-11 2003-09-02 ジョージタウン ユニバーシティー 環式ジペプチドおよびアゼチジノン並びにｃｎｓ損傷および神経変性疾患の治療におけるそれらの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469006A (de) * 1965-07-07 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer synthetischer Alkaloide
CA2121724A1 (en) * 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
AU2002340465A1 (en) * 2001-11-09 2003-05-19 Neuronz Biosciences, Inc. Cyclo(prolyl-glycine) and methods of use to treat neural disorders
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
AU2002363800A1 (en) 2001-11-13 2003-05-26 Loi Tran Therapeutic agent composition and method of use
EP1648873A4 (en) * 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd NEUROPROTECTIVE MACROCYLIC COMPOUNDS AND METHODS OF THEIR APPLICATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525850A (ja) * 1998-02-11 2003-09-02 ジョージタウン ユニバーシティー 環式ジペプチドおよびアゼチジノン並びにｃｎｓ損傷および神経変性疾患の治療におけるそれらの使用

Also Published As

Publication number Publication date
EP1664050B1 (en) 2015-12-09
EP1664050A2 (en) 2006-06-07
JP2007504235A (ja) 2007-03-01
WO2005023815A3 (en) 2005-07-21
WO2005023815A2 (en) 2005-03-17
SI1664050T1 (sl) 2016-04-29
HUE028528T2 (en) 2016-12-28
US8067425B2 (en) 2011-11-29
US20060258663A1 (en) 2006-11-16
DK1664050T3 (en) 2016-03-07
ES2564803T3 (es) 2016-03-29
US20070197511A1 (en) 2007-08-23
US7776876B2 (en) 2010-08-17
PL1664050T3 (pl) 2016-08-31

Similar Documents

Publication Publication Date Title
JP4842817B2 (ja) 神経保護二環式化合物およびその使用方法
US7030118B2 (en) Pyrrolotriazinone compounds and their use to treat diseases
AU774681B2 (en) Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
EP2518067B1 (fr) Dérives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide et leurs applications en thérapeutique comme antagonistes de p2y12.
US8013170B2 (en) Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage
US9926298B2 (en) Heterocyclic compounds and use thereof
ZA200602051B (en) 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7863304B2 (en) Analogs of glycyl-prolyl-glutamate
US9119851B2 (en) Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals
JP2004536069A (ja) Ｇｐｅ類縁体及びペプチドミメティック
US8519127B2 (en) Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
JP2008545697A (ja) グリシル−プロリル−グルタメートの類縁体
CN110719913A (zh) 诱导软骨发生的化合物和组合物
CN115160341B (zh) 苯并噁嗪类化合物及其药物用途
CN105263900A (zh) 用于治疗关节病的羟基亚乙基衍生物
CN1950370B (zh) 对映体纯的六氢吡咯并环戊吡啶-衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110510

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111003

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111006

R150 Certificate of patent or registration of utility model

Ref document number: 4842817

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141014

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term